Comparative study of mammography and mammary serum antigen estimation for breast cancer screening-Reference-Cited by-同舟云学术

Comparative study of mammography and mammary serum antigen estimation for breast cancer screening

Published:1992-08 Issue:3 Volume:157 Page:161-164
ISSN:0025-729X
Container-title:Medical Journal of Australia
language:en
Short-container-title:Medical Journal of Australia

Author:

Ward Bruce G¹,Joy Gloria J¹,Ramm Louise E¹,McGuckin Michael A¹,Baker Christine A²

Affiliation:

1. The University of QueenslandDepartment of Obstetrics and GynaecologyClinical Sciences BuildingRoyal Brisbane HospitalHerstonQLD4029

2. Breast Screening ClinicRoyal Women's HospitalHerstonQLD4029

Publisher

AMPCo

Subject

General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.5694/j.1326-5377.1992.tb137077.x

Reference20 articles.

1. Ten‐ to fourteen‐year effect of screening on breast cancer mortality;Shapiro S;JNCI,1982

2. A New Breast Carcinoma Antigen Defined by a Monoclonal Antibody2

3. Detection of mammary serum antigen in sera from breast cancer patients using monoclonal antibody 3E1.2;Stacker SA;Cancer Res,1988

4. The breast tumorassociated epitope defined by monoclonal antibody 3E1.2 is an O‐linked mucin carbohydrate containing N‐glycolylneuraminic acid. Cancer;Devine PL;Res,1991

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Circulating tumor markers in breast cancer: Accepted utilities and novel prospects;Breast Cancer Research and Treatment;1998-11

2. Circulating tumor markers in breast cancer: Accepted utilities and novel prospects;Prognostic variables in node-negative and node-positive breast cancer;1998

3. CA15-3, CASA, MSA, and TPS as diagnostic serum markers in breast cancer;Breast Cancer Research and Treatment;1995-06

4. Predictive value of the combination of serum markers, CA125, CASA and TPS in ovarian cancer;International Journal of Gynecological Cancer;1995-05

5. Serum mucin antigens casa and msa in tumors of the breast, ovary, lung, pancreas, bladder, colon, and prostate. A blind trial with 420 patients;Cancer;1993-09-15